Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1246-1253

  Robertson, J F R ^a   Steger, G G ^b   Neven, P ^c   Barni, S ^d   Gieseking, F ^e   Nole F ^f   Pritchard, K I ^g   O'Malley, F P ^h   Simon, S D ⁱ   Kaufman, B ^j   Petruzelka, L ^k  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d TREVIGLIO HOSPITAL   (Italy)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^j SHEBA MEDICAL CENTER   (Israel)

^k CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

Advanced breast cancer; Faslodex; Fulvestrant; HER2; Human epidermal growth factor 2

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FULVESTRANT; HORMONE RECEPTOR; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTRADIOL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTLESSNESS; RETROSPECTIVE STUDY; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BREAST NEOPLASMS; CARCINOMA; DISEASE COURSE; EVALUATION STUDY; FEMALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UP-REGULATION;

EID: 77953980796     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp447     Document Type: Article

References (45)

1. Schiff R, Massarweh SA, Shou J et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005; 56 (Suppl 1): 10-20.
2. Wardley AM, Howell A. Does HER2 overexpression affect response to endocrine therapy in advanced cancer? Nat Clin Pract Oncol 2006; 3: 78-79.
3. Arpino G, Green SJ, Allred DC et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10: 5670-5676.
4. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12: 721-747.
5. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001; 8: 191-195.
6. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
7. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24: 85-95.
8. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
9. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11: 4741-4748.
10. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-238.
11. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664-1670.
12. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000; 7: 17-28.
13. Gee JM, Robertson JF, Gutteridge E et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12 (Suppl 1): S99-S111.
14. Osborne CK, Jarman M, McCague R et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89-95.
15. O'Regan RM, Osipo C, Ariazi E et al. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006; 12: 2255-2263.
16. Steger GG, Gips M, Simon SD et al. Fulvestrant ('Faslodex'): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 2005; 31 (Suppl 2): S10-S16.
17. Robertson JFR, Agrawal A, Paish C et al. Activity of fulvestrant in a subset of estrogen receptor-positive patients with advanced breast cancer that overexpress HER2. In Poster 4070 presented at the San Antonio Breast Cancer Symposium, 14-17 December 2006.
18. Petruzelka L, Konopasek B, Pribylova O et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy-updated results from an expanded access programme. Eur J Cancer Suppl 2006; 4: 171.
19. Bartsch R, Wenzel C, Altorjai G et al. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007; 13: 4435-4439.
20. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244.
21. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
22. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
23. Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356: 881-887.
24. Nicholson RI, Hutcheson IR, Harper ME et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8: 175-182.
25. Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001; 12 (Suppl 1): S23-S28.
26. Wludarski SC, Bacchi CE. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol 2008; 16: 466-470.
27. Ricardo SA, Milanezi F, Carvalho ST et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007; 60: 1001-1005.
28. Robertson JF, Dixon AR, Nicholson RI et al. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 1992; 22: 221-227.
29. Johnston SR, Martin LA, Leary A et al. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 2007; 106: 180-186.
30. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
31. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27-36.
32. Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group trial N0032. J Clin Oncol 2006; 24: 1052-1056.
33. Perey L, Paridaens R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18: 64-69.
34. Neven P, Paridaens R, Pelgrims G et al. Fulvestrant (FaslodexAdvPSSym.-1.C228) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 2008; 109: 59-65.
35. Steger GG, Bartsch R, Wenzel C et al. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005; 41: 2655-2661.
36. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 2006; 17: 200-204.
37. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004; 9 (Suppl 3): 20-26.
38. Wong ZW, Isaacs C, Harris L et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl 1): S106.
39. Fulvestrant and/or trastuzumab as first-line therapy in treating postmenopausal women with stage IV breast cancer NCT00138125. http://www.clinicaltrial.gov/ct2/show/NCT00138125(1 September 2009, date last accessed).
40. Li T, Christos P, Sparano JA et al. Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205. J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007; 25: 1037.
41. Bevacizumab given with either anastrozole or fulvestrant with trastuzumab for postmenopausal metastatic breast cancer NCT00405938. http://www.clinicaltrial.gov/ct2/show/NCT00405938(1 September 2009, date last accessed).
42. Fulvestrant with or without lapatinib in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor-positive NCT00390455. http://www.clinicaltrial.gov/ct2/show/NCT00390455 (1 September 2009, date last accessed).
43. Robertson JFR. Fulvestrant (Faslodex)-how to make a good drug better. Oncologist 2007; 12: 774-784.
44. A clinical trial to compare efficacy and tolerability of fulvestrant 250mg, 250mg (plus 250mg loading regimen) and 500mg (FINDER I) NCT00305448. http://www.clinicaltrial.gov/ct2/show/NCT00305448(1 September 2009, date last accessed).
45. Comparison of fulvestrant (FASLODEXAdvPSSym.-1.C228) 250 mg and 500 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previous endocrine therapy. (CONFIRM). NCT00099437. http://www.clinicaltrial.gov/ct2/show/NCT00099437. (1 September 2009, date last accessed).